1. Home
  2. CELC vs BORR Comparison

CELC vs BORR Comparison

Compare CELC & BORR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CELC
  • BORR
  • Stock Information
  • Founded
  • CELC 2011
  • BORR 2016
  • Country
  • CELC United States
  • BORR Bermuda
  • Employees
  • CELC N/A
  • BORR N/A
  • Industry
  • CELC Medical Specialities
  • BORR Oil & Gas Production
  • Sector
  • CELC Health Care
  • BORR Energy
  • Exchange
  • CELC Nasdaq
  • BORR Nasdaq
  • Market Cap
  • CELC 440.0M
  • BORR 481.0M
  • IPO Year
  • CELC 2017
  • BORR 2019
  • Fundamental
  • Price
  • CELC $51.79
  • BORR $2.31
  • Analyst Decision
  • CELC Strong Buy
  • BORR Buy
  • Analyst Count
  • CELC 6
  • BORR 2
  • Target Price
  • CELC $46.50
  • BORR $9.00
  • AVG Volume (30 Days)
  • CELC 2.9M
  • BORR 5.3M
  • Earning Date
  • CELC 08-14-2025
  • BORR 08-13-2025
  • Dividend Yield
  • CELC N/A
  • BORR 6.06%
  • EPS Growth
  • CELC N/A
  • BORR N/A
  • EPS
  • CELC N/A
  • BORR 0.20
  • Revenue
  • CELC N/A
  • BORR $989,000,000.00
  • Revenue This Year
  • CELC N/A
  • BORR $8.35
  • Revenue Next Year
  • CELC N/A
  • BORR $6.39
  • P/E Ratio
  • CELC N/A
  • BORR $12.24
  • Revenue Growth
  • CELC N/A
  • BORR 7.73
  • 52 Week Low
  • CELC $7.58
  • BORR $1.55
  • 52 Week High
  • CELC $53.70
  • BORR $6.82
  • Technical
  • Relative Strength Index (RSI)
  • CELC 92.18
  • BORR 54.55
  • Support Level
  • CELC $38.00
  • BORR $2.14
  • Resistance Level
  • CELC $53.40
  • BORR $2.62
  • Average True Range (ATR)
  • CELC 3.33
  • BORR 0.19
  • MACD
  • CELC 0.92
  • BORR 0.03
  • Stochastic Oscillator
  • CELC 89.44
  • BORR 58.55

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

About BORR Borr Drilling Limited

Borr Drilling Ltd is a drilling contractor that owns and operates jack-up rigs of modern and high-specification designs providing drilling services to the oil and gas exploration and production industry. The company operates a fleet of around 16 jack-up drilling rigs. Geographically the activities are carried out through Norway.

Share on Social Networks: